Characteristics of RCTs evaluating ranibizumab and bevacizumab
| No. included patients | No. anti-VEGF treated patients | Follow-up (months) | Dosage (mg) | No. injections/patient (mean) | Sponsor | |
| Ranibizumab ANCHOR 200912 | 423 | 280 | 24 | 0.3/0.5 monthly | 24 | Pharmaceutical industry |
| Ranibizumab MARINA 20066 | 716 | 478 | 24 | 0.3/0.5 monthly | 21 | Pharmaceutical industry |
| Ranibizumab PIER 2008 13 | 184 | 121 | 12 | 0.3/0.5 3 monthly, then every 3 months | 10 | Pharmaceutical industry |
| Ranibizumab Heier 200614 | 69 | 53 | 7 | 0.3/0.5* | 8 | Not specified |
| Bevacizumab Bashshur 200721 | 64 | 32 | 6 | 2.5 pro re nata | 2.4 | No |
| Bevacizumab Lazic 200722 | 165 | 55 | 3 | 1.25 single injection | 1 | Not specified |
| Bevacizumab Hahn 200723 | 30 | 10 | 3 | 1.0 monthly | 3 | No |
| Bevacizumab Sacu 200924 | 28 | 14 | 12 | 1.0 3 monthly, then pro re nata | 6.8 | Not specified |
↵* Four monthly injections or 1 injection of 0.3 mg followed by three monthly injections of 0.5 mg; after 3 months: crossover design.